BOTHELL, Wash. (AP) -- AVI BioPharma Inc. on Monday named Chris Garabedian as its CEO and president, effective Jan. 1.
Garabedian, 44, replaces interim CEO and president J. David Boyle II, who will stay as chief financial officer and senior vice president. Garabedian has served as vice president of corporate strategy for Celgene Corp. and as vice president of corporate development for Gilead Sciences. He joined the AVI board of directors in June.
AVI, headquartered in Bothell, Wash., focuses on developing treatments for rare and infectious diseases and is developing a potential treatment for Duchenne muscular dystrophy.
Garabedian, 44, replaces interim CEO and president J. David Boyle II, who will stay as chief financial officer and senior vice president. Garabedian has served as vice president of corporate strategy for Celgene Corp. and as vice president of corporate development for Gilead Sciences. He joined the AVI board of directors in June.
AVI, headquartered in Bothell, Wash., focuses on developing treatments for rare and infectious diseases and is developing a potential treatment for Duchenne muscular dystrophy.
